Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag
2026-03-05 17:20:00 ET
Regencell Bioscience (NASDAQ: RGC) is an early-stage bioscience company. That alone should be enough to keep most investors on the sidelines, given the risks involved if the medicines the company is working on fail to produce positive results. However, there's another small wrinkle here. Regencells Bioscience is working on something it calls TCM. What is TCM?
Early-stage healthcare companies are fraught with risk. In essence, they are companies that believe something could be a valuable product, but they still have to test it to make sure. It costs huge sums of money to develop, test, and get medicines approved for human use. So companies like Regencell Bioscience often tap the capital markets for cash.
Image source: Getty Images.
NASDAQ: RGC
RGC Trading
2.02% G/L:
$24.75 Last:
43,926 Volume:
$24.21 Open:
